Arrowhead Pharmaceuticals Stock News & Updates

[WKN: A2AGYB | Symbol: ARWR]

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals: Morgan Stanley upgrades to Overweight with target of $100 - Focus on price increase above resistance line

04/21/2026 at 01 PM

Uber Technologies [US90353T1007] TD Cowen maintains Buy rating with a price target of $114 (47% upside...

01/07/2026 at 09 AM

Microchip Technology (MCHP) – Turnaround in the Chip Sector: Revenue Guidance Raised Thanks to Strong...

01/06/2026 at 05 PM

US Markets Up – Investors Focus on Tech Despite Geopolitical Tensions The US stock markets continue...

12/19/2025 at 04 PM

For my last article in this column for the calendar year 2025, I took another look at the three megatrends...

12/12/2025 at 05 PM

Business drivers: Arrowhead Pharmaceuticals (ARWR) has focused on the development and commercialization...

12/02/2025 at 01 PM

TUI [DE000TUAG505] JPMorgan confirms Overweight rating and adjusts the price target from 13.00...

11/27/2025 at 05 PM

Arrowhead has a leading technology in the field of RNA interference (RNAi) with its proprietary TRiM™...

11/27/2025 at 02 PM

With REDEMPLO, $829 million in revenue, and nearly reaching profitability, Arrowhead makes the leap...

08/26/2025 at 05 PM

Two weeks ago, I introduced five AI stocks that are currently taking off. Since, in addition to this...

08/26/2025 at 11 AM

Market penetration for RNAi-based therapies is imminent. Back in November 2024, I reported that Arrowhead...